CDXS (Codexis Bio) Company Profit

Official company branding of codexis.com (CDXS)

Codexis, Inc. (CDXS) specializes in creating advanced medical drugs and diagnostic systems through nucleic acid manipulation. This daily price chart reflects the performance of the company, which currently stands at -0.03. The business leverages cutting-edge synthetic biology to develop affordable biocatalysts. These solutions optimize chemical cycles within the food and pharmaceutical industries, significantly reducing production costs.

Net Income: Codexis, Inc. (CDXS) for 07/04/2022 - 10/29/2026

Analytical breakdowns and data insights for company codexis.com (CDXS)

- stock value and consensus price forecast:
Market Price Codexis|CDXS - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization CDXS|CDXS - Enterprise Value
- book capitalization information:
Net Asset Value per Share Codexis, Inc.|CDXS - Company Net Assets|Capitalization to Book Value Ratio codexis.com|CDXS - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Capital Coefficient Codexis, Inc.|CDXS - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Codexis|CDXS - Company Total Debt|Debt to Net Assets Ratio CDXS|CDXS - Company Long-Term Debts|Short-Term Debt Volume Codexis, Inc.|Immediate Liquidity Ratio codexis.com
- company profitability and valuation multiples indicators:
CDXS - Net Profit
Summary company analysis:Codexis Bio (CDXS)
Mass-produced product of Codexis Bio

Fundamental analysis of Codexis, Inc. (CDXS) requires a precise assessment of the business's ability to generate free cash flow. This metric captures the daily cash balance remaining after deducting all operating and tax expenses. By analyzing the company's profit history, an investor determines financial stability and scaling rates. Growth in this indicator confirms the commercial efficiency of implementing "green chemistry" and eco-friendly enzymes. Positive momentum signals the monetization of ESG innovations.

Direct competitors

Company Net Income Tempus AI (TEM)|QGEN (Qiagen N.V.) - Net Profit|Company Profit IONS (ionispharma.com)|Net Profit RGEN|RNA - Company Net Income|CRISPR Therapeutics Corp - Net Income|WGS: Company Profit|Ultragenyx Pharmaceutical - Net Profit|Net Financial Result beamtx.com BEAM|Sarepta (SRPT) - Company Net Income|TWST - Net Financial Result|Net Income TXG|NTLA: Final Profit|Net Profit STOK|Net Financial Result biolifesolutions.com|Company Net Income Wave Life Sciences Ltd. WVE|MAZE: Company Profit|Sionna Pharma - Net Profit|Prime Medicine Bio (PRME) - Net Income|TSHA (Taysha Gene Therapies) - Net Income|QURE - Net Financial Result|MGTX (MeiraGTx) - Net Profit|Net Income REGENXBIO Inc (RGNX)|Net Profit SLDB|Ocugen Pharma - Company Profit|Pacific Biosciences - Net Income|BNTC: Company Profit|DSGN - Company Net Income|Net Financial Result Rocket Pharma RCKT|FDMT: Net Profit|Company Profit LXEO|Company Net Income Korro Bio Inc.|Company Profit EDIT (editasmedicine.com)|Net Profit SLN|Net Profit proqr.com (PRQR)|Net Profit SGMO (Sangamo)|NAUT - Net Income|MGX - Company Net Income|Company Net Income Precision BioSciences Inc.|GBIO: Net Profit|Company Profit BOLD|XCUR (Exicure Inc.) - Net Profit|Company Net Income Celsion Corporation IMNN|Net Income PHIO (Phio Pharmaceuticals)|mustangbio.com - Company Profit|Net Profit RNAZ (TransCode Therapeutics, Inc.)|Net Financial Result Bionano Genomics Inc. (BNGO)|APDN - Company Net Income|Net Financial Result bluebird bio, Inc BLUE|IPA (immunoprecise.com) - Net Income|omegatherapeutics.com - Final Profit|OMIC (Singular Genomics) - Net Profit|Regulus Therapeutics, Inc. (RGLS) - Net Financial Result|Company Net Income Syros (SYRS)|Telesis Bio, Inc - Company Profit|Net Profit TCON (TRACON Pharmaceuticals)|UBX - Net Income